Replies to post #334881 on Anavex Life Sciences Corp (AVXL)

[JWC3]

The 413 is actually $13.

[Steady_T]

If I see $3466 SP I won't pass out, I'll need a crash cart.

But them maybe I'll be used to massive SP increases by then.

[ignatiusrielly35]

Revenue has no connection to a PE ratio. PE is price-earnings, not price-revenue.

[tredenwater2]

Let me understand YOUR calculation. You say at that time of the great P3 AD reveal, that event will make the AVXL MC $20B!
So $20B/75M shares = $266. So I question YOUR ASSUMPTION of $20B MC!

Yes, correct, all speculation but 20 billion at the time of the release. If we are say trading in the $50-$70 range from Rett Syndrome approval, great PDD data etc, when news hits we will escalate quickly to $100,$150, Stock halt…., $200,$250, even $300! Then the lull sets in and max pain is applied driving the price back down to $200-$250 range until revenue and reimbursement codes get set up by insurance companies. Very quickly with in the first year after approval we may hit $400,$500 a share but its going to take a smooth roll out ( which I do not doubt Dr M is currently laying the foundation for) to get the revenue stream flowing and fast. Between year 1-2 we are a revenue flowing machine and yes 20x earnings is average, may be way more, and $1250+ is way possible.

The real excitement is the lead up to the anticipated results from the preventative Alzheimer’s trial 5 years out. Of course with Parkinsons approval, upon a positive Ph 3 and a few 3 rare disease approvals too, we may reach the numbers you are talking about. Somewhere in all this craziness on the way to prophylactic use is a couple of 4-1 forward splits or 1 massive 10-1 forward split.

Fun to speculate

Cheers